Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Rochester
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Marmara University
M.D. Anderson Cancer Center
City of Hope Medical Center
Children's Oncology Group
Faron Pharmaceuticals Ltd
M.D. Anderson Cancer Center
Pfizer